Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The oncogene ERG: a key factor in prostate cancer.

Literature DB >> 25915839

The oncogene ERG: a key factor in prostate cancer.

Abstract

ETS-related gene (ERG) is a member of the E-26 transformation-specific (ETS) family of transcription factors with roles in development that include vasculogenesis, angiogenesis, haematopoiesis and bone development. ERG's oncogenic potential is well known because of its involvement in Ewing's sarcoma and leukaemia. However, in the past decade ERG has become highly associated with prostate cancer development, particularly as a result of a gene fusion with the promoter region of the androgen-induced TMPRRSS2 gene. We review ERG's structure and function, and its role in prostate cancer. We discuss potential new therapies that are based on targeting ERG.

Entities: Disease Gene

Mesh：

Substances：

Year: 2015 PMID： 25915839 DOI： 10.1038/onc.2015.109

Source DB: PubMed Journal: Oncogene ISSN： 0950-9232 Impact factor: 9.867

203 in total

1. Imaging Erg and Jun transcription factor interaction in living cells using fluorescence resonance energy transfer analyses.

Authors: Barbara Camuzeaux; Corentin Spriet; Laurent Héliot; Jean Coll; Martine Duterque-Coquillaud
Journal: Biochem Biophys Res Commun Date: 2005-07-15 Impact factor: 3.575

2. miR-141 modulates androgen receptor transcriptional activity in human prostate cancer cells through targeting the small heterodimer partner protein.

Authors: Jing Xiao; Ai-Yu Gong; Alex N Eischeid; Dongqing Chen; Caishu Deng; Charles Y F Young; Xian-Ming Chen
Journal: Prostate Date: 2012-02-07 Impact factor: 4.104

3. Interaction of murine ets-1 with GGA-binding sites establishes the ETS domain as a new DNA-binding motif.

Authors: J A Nye; J M Petersen; C V Gunther; M D Jonsen; B J Graves
Journal: Genes Dev Date: 1992-06 Impact factor: 11.361

4. Determinants of DNA-binding specificity of ETS-domain transcription factors.

Authors: P Shore; A J Whitmarsh; R Bhaskaran; R J Davis; J P Waltho; A D Sharrocks
Journal: Mol Cell Biol Date: 1996-07 Impact factor: 4.272

5. The proto-oncogene ERG is a target of microRNA miR-145 in prostate cancer.

Authors: Martin Hart; Sven Wach; Elke Nolte; Jaroslaw Szczyrba; Roopika Menon; Helge Taubert; Arndt Hartmann; Robert Stoehr; Wolf Wieland; Friedrich A Grässer; Bernd Wullich
Journal: FEBS J Date: 2013-04-08 Impact factor: 5.542

6. Inhibition of vimentin or beta1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo.

Authors: Xueping Zhang; Marcia V Fournier; Joy L Ware; Mina J Bissell; Adly Yacoub; Zendra E Zehner
Journal: Mol Cancer Ther Date: 2009-03-10 Impact factor: 6.261

7. Complex patterns of ETS gene alteration arise during cancer development in the human prostate.

Authors: J Clark; G Attard; S Jhavar; P Flohr; A Reid; J De-Bono; R Eeles; P Scardino; J Cuzick; G Fisher; M D Parker; C S Foster; D Berney; G Kovacs; C S Cooper
Journal: Oncogene Date: 2007-10-08 Impact factor: 9.867

8. Ets proteins: new factors that regulate immunoglobulin heavy-chain gene expression.

Authors: R R Rivera; M H Stuiver; R Steenbergen; C Murre
Journal: Mol Cell Biol Date: 1993-11 Impact factor: 4.272

9. Human ERG is a proto-oncogene with mitogenic and transforming activity.

Authors: A H Hart; C M Corrick; M J Tymms; P J Hertzog; I Kola
Journal: Oncogene Date: 1995-04-06 Impact factor: 9.867

10. The genomic complexity of primary human prostate cancer.

Authors: Michael F Berger; Michael S Lawrence; Francesca Demichelis; Yotam Drier; Kristian Cibulskis; Andrey Y Sivachenko; Andrea Sboner; Raquel Esgueva; Dorothee Pflueger; Carrie Sougnez; Robert Onofrio; Scott L Carter; Kyung Park; Lukas Habegger; Lauren Ambrogio; Timothy Fennell; Melissa Parkin; Gordon Saksena; Douglas Voet; Alex H Ramos; Trevor J Pugh; Jane Wilkinson; Sheila Fisher; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jonathan W Simons; Naoki Kitabayashi; Theresa Y MacDonald; Philip W Kantoff; Lynda Chin; Stacey B Gabriel; Mark B Gerstein; Todd R Golub; Matthew Meyerson; Ashutosh Tewari; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal: Nature Date: 2011-02-10 Impact factor: 49.962

72 in total

Review 1. The Untranslated Regions of mRNAs in Cancer.

Authors: Samantha L Schuster; Andrew C Hsieh
Journal: Trends Cancer Date: 2019-03-22

Review 2. Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer.

Authors: Shan Wang; Dede N Ekoue; Ganesh V Raj; Ralf Kittler
Journal: Cancer Lett Date: 2018-09-11 Impact factor: 8.679

Review 3. Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.

Authors: Loredana Puca; Panagiotis J Vlachostergios; Himisha Beltran
Journal: Cold Spring Harb Perspect Med Date: 2019-02-01 Impact factor: 6.915

Review 4. The role of GATA2 in lethal prostate cancer aggressiveness.

Authors: Veronica Rodriguez-Bravo; Marc Carceles-Cordon; Yujin Hoshida; Carlos Cordon-Cardo; Matthew D Galsky; Josep Domingo-Domenech
Journal: Nat Rev Urol Date: 2016-11-22 Impact factor: 14.432

5. Dynamic regulation of VEGF-inducible genes by an ERK/ERG/p300 transcriptional network.

Authors: Jason E Fish; Manuel Cantu Gutierrez; Lan T Dang; Nadiya Khyzha; Zhiqi Chen; Shawn Veitch; Henry S Cheng; Melvin Khor; Lina Antounians; Makon-Sébastien Njock; Emilie Boudreau; Alexander M Herman; Alexander M Rhyner; Oscar E Ruiz; George T Eisenhoffer; Alejandra Medina-Rivera; Michael D Wilson; Joshua D Wythe
Journal: Development Date: 2017-05-23 Impact factor: 6.868

Review 6. Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine.

Authors: M J Alvarez-Cubero; L J Martinez-Gonzalez; I Robles-Fernandez; J Martinez-Herrera; G Garcia-Rodriguez; M Pascual-Geler; J M Cozar; J A Lorente
Journal: Mol Diagn Ther Date: 2017-04 Impact factor: 4.074

7. Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.

Authors: Ahmed A Mohamed; Shyh-Han Tan; Charles P Xavier; Shilpa Katta; Wei Huang; Lakshmi Ravindranath; Muhammad Jamal; Hua Li; Meera Srivastava; Eri S Srivatsan; Taduru L Sreenath; David G McLeod; Alagarsamy Srinivasan; Gyorgy Petrovics; Albert Dobi; Shiv Srivastava
Journal: Mol Cancer Res Date: 2017-06-12 Impact factor: 5.852